The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial.
Kelly-Anne Phillips
No relevant relationships to disclose
Karin Ribi
No relevant relationships to disclose
Julie Aldridge
No relevant relationships to disclose
Alastair Mark Thompson
Honoraria - Novartis
Vernon J. Harvey
No relevant relationships to disclose
Beat J. K. Thurlimann
Stock Ownership - Novartis
Fatima Cardoso
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Olivia Pagani
No relevant relationships to disclose
Alan Stuart Coates
No relevant relationships to disclose
Aron Goldhirsch
Honoraria - Novartis
Karen N. Price
No relevant relationships to disclose
Richard D. Gelber
No relevant relationships to disclose
Juerg Bernhard
No relevant relationships to disclose